Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

BMO cuts Novo Nordisk stock target from USD 47.00 to USD 40.00

Analyst downgrade AI-generated analysis

πŸ“‰ BMO Capital lowered its Novo Nordisk price target from USD 47.00 to USD 40.00 on October 12, 2026.

πŸ“Š Q2 2026 adjusted sales reached DKK 78.49 billion, up 7% at constant exchange rates.

πŸ’° Adjusted operating profit for Q2 2026 increased by 11% to DKK 33.39 billion.

⚠️ The company recorded a DKK 6.30 billion non-cash impairment charge linked to intangible pipeline assets.

πŸ“ˆ Full-year 2026 guidance for adjusted sales and operating profit growth was revised to 0% to -6%.

πŸ”¬ Novo Nordisk targets more than five multi-blockbuster launches by 2030 with over DKK 150 billion in pipeline sales by 2035.

πŸ’Š Analyst concerns focus on the uptake of Wegovy HD injectable and expectations for pill-based growth.

πŸ“… Next quarterly results are scheduled for November 4, 2026, before market open.

🏒 Novo Nordisk stock traded at EUR 34.66 with a market cap of USD 171.3 billion as of October 12.

Bullish Signals
  • Novo Nordisk reported adjusted Q2 2026 sales growth of 7% and adjusted operating profit growth of 11%, demonstrating strong operational performance.
  • The company revised its full-year 2026 guidance for adjusted sales and operating profit growth to a range of 0% to -6%, which is an improvement over the prior expectation of -4% to -12%.
  • Novo Nordisk has set an ambitious strategy targeting more than five multi-blockbuster launches by 2030, projecting risk-adjusted pipeline sales of over DKK 150 billion by 2035.
Risk Factors
  • BMO Capital lowered its price target from USD 47.00 to USD 40.00 due to concerns about Wegovy HD injectable uptake and lower-than-expected pill-growth expectations.
  • The company recognized a DKK 6.30 billion non-recurring, non-cash impairment charge linked to intangible pipeline assets in Q2 2026.
Full Analysis
BMO Capital Management has lowered its price target for Novo Nordisk from USD 47.00 to USD 40.00, citing concerns regarding the uptake of the Wegovy HD injectable and lower-than-expected growth in oral medication segments. Despite this downgrade, BMO maintained a Market Perform rating, signaling that the investment case relies heavily on near-term execution capabilities rather than long-term pipeline potential. The stock was trading at EUR 34.66 on October 13, 2026, with a market capitalization of USD 171.3 billion. Novo Nordisk reported adjusted Q2 2026 sales of DKK 78.49 billion, representing a 7% increase at constant exchange rates, while adjusted operating profit rose by 11% to DKK 33.39 billion. However, the company recorded a significant non-cash impairment charge of DKK 6.30 billion related to intangible pipeline assets. For the full year 2026, Novo Nordisk has revised its guidance for adjusted sales and operating profit growth to a range between 0% and -6%, which is an improvement from the previously expected decline of -4% to -12%. The company outlined a strategic roadmap targeting more than five multi-blockbuster launches by 2030, with risk-adjusted pipeline sales projected to exceed DKK 150 billion by 2035. Investors will closely watch the upcoming quarterly results scheduled for November 4, 2026, which are expected to test the validity of the company's revised annual outlook and its ability to address the specific growth concerns highlighted by BMO.